Cardiff Oncology
CRDF
33 hedge funds and large institutions have $1.32M invested in Cardiff Oncology in 2018 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
14% more funds holding
Funds holding: 29 → 33 (+4)
10% more capital invested
Capital invested by funds: $1.21M → $1.32M (+$115K)
3.76% less ownership
Funds ownership: 5.29% → 1.53% (-3.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$310K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$158K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$101K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$69.4K |
| 5 |
DY
Dowling & Yahnke
San Diego,
California
|
+$49.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$471K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$237K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.15K |
| 4 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
-$1.74K |
| 5 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
-$1K |
CRDF Hedge Fund Activity: Q3 2018 in Review
33 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q3 2018, worth a combined $1.32M — up 9.5% from $1.21M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CRDF positions and 5 closed out — a net gain of 4 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $310K. The largest seller was Sabby Management, cutting an estimated $471K.
- 33 institutional investors held Cardiff Oncology (CRDF) as of Q3 2018, up from 29 in Q2 2018.
- Funds reported $1.32M of Cardiff Oncology stock for Q3 2018, up 9.5% quarter-over-quarter.
- 9 funds opened new Cardiff Oncology positions in Q3 2018 and 5 closed out, a net change of +4 holders.
- The largest Cardiff Oncology buyer in Q3 2018 was Renaissance Technologies, an estimated $310K added.
- The largest Cardiff Oncology seller in Q3 2018 was Sabby Management, an estimated $471K sold.
Based on aggregated 13F filings for Q3 2018.